Autism awards: $400,000 CDMRP opportunity

Dear Friends and Colleagues,

The Congressionally Directed Medical Research Programs (CDMRP’s) issued annually by the Department of Defense, are an excellent source of funding for several key areas of research ranging from ALS, through various Oncology programs to Multiple Sclerosis.

Awards up to $400,000 for Autism Spectrum Disorders(ADS) are the latest opportunities to be issued by the CDRMP. Pre-applications are due June 20th, 2012. 

The FreeMind Group has extensive experience in assisting clients in completing and winning such complex and competitive proposals. Through our methodical and proven professional process we will guide your efforts through to submission and subsequent award.

Idea Development Award

Funding: $400,000 for direct costs (plus indirect costs) for up to 3 years

Pre-application: (required): June 20, 2012

Full Application (upon invitation): September 20, 2012

Scope: Supports the development of innovative, high-impact ideas that advance the understanding of autism spectrum disorders (ASD) and lead to improved outcomes.

Applications in the following areas are encouraged:

  • Improved sub-grouping of individuals with ASD to inform the mechanisms, natural history, and response to treatment (e.g., biomarkers, risk factors, sex ratio).
  • Identification of therapeutic targets, excluding new gene discovery.
  • Psychosocial research across the lifespan, including  influences in brain function/structure.
  • Co-morbid conditions across the lifespan, especially sleep disorders and gastrointestinal issues.

Preliminary data are required. Clinical trials are not allowed.

 

  For more information

 

Pilot Award 

Funding: $100,000 for direct costs (plus indirect costs) for up to 2 years

Pre-application (required): June 20, 2012

Full Application (upon invitation): September 20, 2012

Scope: Supports conceptually innovative, high-risk/high-reward research that could ultimately lead to critical discoveries or major advancements that will drive the field of ASD forward.

Applications in the following areas are encouraged:

  • Improved sub-grouping of individuals with ASD to inform the mechanisms, natural history, and response to treatment (e.g., biomarkers, risk factors, sex ratio).
  • Identification of therapeutic targets, excluding new gene discovery.
  • Psychosocial research across the lifespan, including  influences in brain function/structure.
  • Co-morbid conditions across the lifespan, especially sleep disorders and gastrointestinal issues.

Preliminary data not allowed. Clinical trials are not allowed. Not intended to support the continuation of existing studies or the next logical extension and/or incremental step.

For more information

For additional information please contact Hannah Rosencweig at:

(617) 648-0340hannah@freemindconsultants.com

Best regards,

Ayal Ronen
Vice President
FreeMindGroup

www.freemindconsultants.com